Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Paclitaxel + SPC3042|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|SPC3042||SPC-3042||SPC3042 is an antisense oligonuecliotide that targets Survivin leading to decreased Survivin expression, which may result in increased tumor cell apoptosis and increased sensitivity to chemotherapeutics (PMID: 18790754, PMID: 20024838).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||Paclitaxel + SPC3042||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of SPC3042 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in prostate cancer cell line xenograft models, with increased activity over either agent alone (PMID: 18790754).||18790754|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|